Sildenafil
Product Images NDC 68071-2552

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-2552). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2552 5)

Packaging label for Sildenafil 50mg tablets from NuCare Pharmaceuticals, Inc., NDC 68071-2552-5. The label indicates 15 tablets per package, with each film-coated tablet containing 50mg sildenafil citrate. The tablets are round, white, and debossed with '1' on one side and '36' on the other. Manufactured by Hetero Labs Limited in Hyderabad, India.*

FDA Label Image

Camberlogo1 (Camberlogo1)

FDA Label Image

Camberlogo2 (Camberlogo2)

FDA Label Image

Sildenafilfigure7 (Sildenafilfigure7)

A bar chart depicting the percentage of patients reporting improvement across four treatment groups: Placebo, Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. The graph shows increasing improvement percentages from placebo (24%) through 25 mg (63%), 50 mg (74%), to 100 mg (82%) dose groups.*

FDA Label Image

Sildenafilfigure1 (Sildenafilfigure1)

A line graph comparing the effect of Sildenafil 100 mg and placebo on systolic blood pressure (mmHg) over 24 hours post dose. The x-axis represents time post dose in hours, and the y-axis shows changes in systolic blood pressure. Trends for both Sildenafil and placebo groups are plotted.*

FDA Label Image

Sildenafilfigure2 (Sildenafilfigure2)

A line graph showing change in blood pressure (mmHg) over time (hours) for two treatments: placebo and Cialis (Tadalafil) 25 mg. The x-axis represents time postdose (hours) and the y-axis shows the blood pressure change. The graph compares the effects of the two treatments with plotted data points and lines.*

FDA Label Image

Sildenafilfigure3 (Sildenafilfigure3)

A line graph comparing plasma concentrations over time (in hours) for Dronedarone alone and Dronedarone with Sildenafil 50 mg. The vertical axis shows change in plasma concentration, while the horizontal axis shows time postdose up to 8 hours. Two color-coded lines track the changes for the two conditions.*

FDA Label Image

Sildenafilfigure4 (Sildenafilfigure4)

Line graph comparing mean arterial pressure over 8 hours after dosing between two groups: one treated with Doxazosin plus Sildenafil 100 mg and the other with Doxazosin plus placebo. The x-axis shows time after dosing in hours, and the y-axis shows mean arterial pressure changes in mmHg.*

FDA Label Image

Sildenafilfigure5 (Sildenafilfigure5)

A pharmacokinetic curve graph showing plasma concentration (ng/mL) of Sildenafil over time (hours) after a dose. The data points track the concentration of the commercial tablet formulation from 0 to 24 hours post-dose.*

FDA Label Image

Sildenafilfigure6a (Sildenafilfigure6a)

A bar chart showing the percentage of patients at endpoint grouped by baseline score categories (0 to 5). Multiple bars represent different score levels (0 to 5) indicating varying patient percentages across each baseline score group.*

FDA Label Image

Sildenafilfigure6b (Sildenafilfigure6b)

A bar chart illustrating the percentage of patients at endpoint categorized by baseline score, with multiple data series indicated by a legend on the right numbered 00 to 05. The x-axis represents baseline scores from 0 to 5, and the y-axis shows the percentage of patients, ranging from 0 to 80%. Each baseline score has several bars representing different groups or conditions.*

FDA Label Image

Sildenafilheterologo1 (Sildenafilheterologo1)

FDA Label Image

Sildenafilheterologo2 (Sildenafilheterologo2)

FDA Label Image

Sildenafilstructure (Sildenafilstructure)

Chemical structure of Sildenafil, showing its molecular framework including sulfonamide, piperazine, and pyrazolopyrimidinone moieties, as well as the citrate counterion structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.